EBV-VLP Pulsed B Cells for CD4+ T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating EBV-specific T cell lines are inefficient and pose health risks due to the use of transforming EBV DNA, which complicates the production of CD4+ T cells specific for EBV structural antigens, and result in variable and less effective immune responses.
Innovation Solution
The use of Epstein-Barr virus-like particles (EB-VLPs) devoid of transforming viral DNA, which are loaded onto B cells to present EBV structural antigens on MHC II, allowing for the efficient isolation and expansion of CD4+ T cells specific for EBV structural antigens without the risk of transforming B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional LCL-based methods are used to generate EBV-specific T cell lines, then T cell expansion is achieved, but the risk of transforming B cells with EBV DNA increases and production efficiency decreases
Solution Approach 1:
The patent extracts and removes the transforming EBV DNA from the system while retaining the useful EBV structural antigens. Virus-like particles (VLPs) are used that contain only the structural proteins needed for antigen presentation, deliberately excluding the viral genome that causes transformation. This separation allows safe antigen delivery without the harmful transforming DNA.
Solution Approach 2:
The patent introduces B cells as an intermediary carrier to present EBV structural antigens to T cells. Instead of using LCLs that require EBV DNA transformation, normal B cells are used as antigen-presenting cells that can be safely pulsed with VLPs. This intermediary approach enables antigen presentation without the need for transformed cell lines.
2Productivity
If LCL-based stimulation is used, then CD4+ T cell expansion is achieved, but the time required for production increases due to extensive in vitro culture
Solution Approach 1:
The patent performs preliminary preparation of antigen-presenting B cells by pulsing them with VLPs before T cell stimulation. This pre-loading of antigens onto B cells eliminates the need for lengthy LCL establishment and expansion phases, allowing direct stimulation of T cells with pre-prepared antigen-presenting cells, thereby significantly reducing production time.
3Reliability
If polyclonal EBV-specific T cell lines are prepared by repeated stimulation with LCL, then T cell responses are generated, but the CD4+ T cell component is depleted and immune evasion occurs
Solution Approach 1:
The patent applies local quality by specifically targeting and enriching for CD4+ T cells with antigen specificity against EBV structural antigens. By using VLP-pulsed B cells as stimulators, the method creates a localized immune response focused on structural antigens presented by MHC class II molecules, thereby enriching for the desired CD4+ T cell population while maintaining broad antigen coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the rapid and efficient generation of CD4+ T cell lines specifically targeting EBV structural antigens, reducing the time and risk associated with traditional LCL-based methods, and enhances the clinical efficacy of EBV-specific T cell preparations.
Implementation Method 1
which are efficiently presented on MHC II following CD21-mediated uptake of EBV particles by B cells
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.